Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar) on September 22, 2015. The report discloses the entry into a material definitive agreement with Glenmark Pharmaceuticals Ltd. (Glenmark) regarding the manufacturing of crofelemer for animal health use.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement and does not contain financial statement data.
Material Changes
The primary material change is the execution of a four-year manufacturing and supply agreement with Glenmark. Under this agreement, Glenmark will serve as Jaguar's manufacturer for crofelemer intended for animal health applications. The agreement covers manufacturing specifications, forecasting, ordering, delivery, payment terms, confidentiality, and indemnification.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the agreement and the attachment of a press release dated September 28, 2015. The filing notes that certain portions of the full agreement are subject to a request for confidential treatment under Rule 24b-2 and will be filed with the subsequent Form 10-Q. No specific financial guidance or new risk factors were disclosed in this text.
Key Facts for Investor Verification
- Verify the full terms of the manufacturing agreement once filed as an exhibit to the Form 10-Q for the period ending September 30, 2015.
- Confirm the specific financial obligations and payment terms within the confidential portions of the agreement.
- Review the September 28, 2015 press release (Exhibit 99.1) for additional strategic context.
- Monitor future filings for any impact of this agreement on Jaguar's supply chain and cost structure.